Virginia Hemp and Marijuana Regulation: Complete Legal Guide

Executive Summary

Virginia operates a dual-track cannabis system where adult-use marijuana remains legal to possess but not to sell, while hemp-derived intoxicating cannabinoids face mounting regulatory pressure from both state and federal authorities. The Commonwealth legalized simple possession of up to one ounce of marijuana in July 2021 under House Bill 2312, but the General Assembly has repeatedly failed to establish a regulated retail market, leaving consumers in a legal gray area. Meanwhile, Virginia's hemp industry—valued at over $150 million annually—confronts an uncertain future as the U.S. Drug Enforcement Administration advances Schedule III reclassification for marijuana and state lawmakers debate restrictions on delta-8 THC and other hemp-derived intoxicants. Farmers who invested millions in hemp cultivation infrastructure now face potential crop destruction if federal or state rules tighten, while unlicensed retailers selling intoxicating hemp products operate in a regulatory vacuum. The Virginia Cannabis Control Authority, established in 2021, has issued fewer than 500 conditional licenses for a retail market that may never open, and the state's four operational medical dispensaries serve approximately 50,000 registered patients. As of June 2026, Virginia stands at a crossroads: federal rescheduling could preempt state hemp regulations, the General Assembly may finally authorize adult-use sales in the 2027 session, or the status quo could persist indefinitely, leaving Virginia as one of the nation's most contradictory cannabis jurisdictions.

Why This Matters

Virginia's regulatory paralysis affects 8.6 million residents, hundreds of farmers, thousands of retail employees, and billions in potential tax revenue. The Commonwealth's hemp industry employs an estimated 3,200 workers across cultivation, processing, and retail, according to Virginia Department of Agriculture and Consumer Services data from 2025. Hemp farmers cultivated approximately 2,800 acres in 2025, down from a 2019 peak of 8,100 acres, as market uncertainty and federal enforcement threats drove consolidation. The Virginia Hemp Coalition estimates that 40 percent of the state's licensed hemp processors have ceased operations since 2023, unable to secure banking services or navigate conflicting state and federal guidance. For medical cannabis patients, the stakes are clinical. Virginia's medical program serves patients with conditions including cancer, glaucoma, HIV/AIDS, cachexia, seizures, and intractable pain, but the four licensed pharmaceutical processors—Dharma Pharmaceuticals, Columbia Care, Green Leaf Medical, and gLeaf Medical Virginia—operate only 11 dispensary locations statewide. Patients in Southwest Virginia often drive over 100 miles to reach the nearest dispensary, and the program's restrictive qualifying conditions exclude common debilitating disorders like anxiety and insomnia that qualify in neighboring states. The fiscal implications are substantial. The Joint Legislative Audit and Review Commission projected in 2020 that a regulated adult-use market could generate $300 million to $500 million in annual sales by year five, producing $30 million to $50 million in state tax revenue. Virginia currently collects zero excise tax revenue from cannabis, while neighboring Maryland collected $157 million in adult-use cannabis taxes in fiscal year 2025 and Washington, D.C. collected $52 million. The Commonwealth's failure to establish retail sales has diverted hundreds of millions in consumer spending to illicit markets, neighboring states, and unregulated hemp retailers. Law enforcement resources remain strained. Virginia State Police reported 4,200 marijuana-related arrests in 2025, down from 29,000 in 2020 but still representing significant criminal justice expenditure for a substance that is legal to possess. Prosecutors and courts continue to handle cases involving distribution, cultivation beyond the four-plant home-grow limit, and public consumption, while police struggle to distinguish legal hemp from illegal marijuana without expensive laboratory testing.

Background and History

Virginia's path from absolute prohibition to partial legalization spans a century of incremental reform, with the past decade bringing unprecedented change.

Early Prohibition Era (1930s-2000s)

Virginia criminalized marijuana possession in 1934, two years before the federal Marihuana Tax Act of 1937. For seven decades, the Commonwealth maintained some of the nation's strictest cannabis penalties. Until 2020, possession of even trace amounts constituted a criminal misdemeanor punishable by up to 30 days in jail and a $500 fine under Virginia Code § 18.2-250.1. A second offense carried up to one year imprisonment. Distribution of any amount was a felony with a mandatory minimum sentence, and cultivation of a single plant constituted felony manufacturing. The War on Drugs era brought escalating enforcement. Virginia police made over 24,000 marijuana arrests annually throughout the 1990s and 2000s, with African Americans arrested at three times the rate of white Virginians despite similar usage rates, according to ACLU data. These disparities persisted across urban and rural jurisdictions, from Richmond to Roanoke to Virginia Beach.

Medical Cannabis Authorization (2015-2021)

Virginia's medical cannabis program emerged through incremental legislation. In 2015, Governor Terry McAuliffe signed Senate Bill 1235, creating an affirmative defense for possession of cannabidiol oil or THC-A oil for treatment of intractable epilepsy. The law required a doctor's written certification but established no legal source for the medicine, forcing families to travel to Colorado or California. The 2017 General Assembly passed House Bill 2293, directing the Board of Pharmacy to register five pharmaceutical processors to cultivate and dispense medical cannabis. The legislation limited the program to epilepsy patients and required vertical integration—each processor would handle cultivation, extraction, and retail. The Cannabis Control Authority predecessor, the Board of Pharmacy, awarded licenses in 2018 to five applicants: Dharma Pharmaceuticals (Bristol), Columbia Care (Portsmouth), Green Leaf Medical (Richmond), gLeaf Medical Virginia (Salem), and Dalitso LLC (Manassas). Dalitso later withdrew, leaving four operational processors. In 2018, House Bill 1251 expanded qualifying conditions to include any condition for which a practitioner issues a written certification, effectively creating practitioner discretion. The program launched in March 2020 with the first dispensary openings. By December 2020, approximately 8,000 patients had registered, and the four processors operated seven dispensary locations.

Decriminalization and Legalization (2020-2021)

The 2020 General Assembly passed House Bill 972 and Senate Bill 2, decriminalizing simple possession of up to one ounce of marijuana. Effective July 1, 2020, first-time possession became a civil violation punishable by a $25 fine with no criminal record. The legislation directed the Crime Commission to study the impact of legalizing marijuana and the Joint Legislative Audit and Review Commission to study the Commonwealth's potential regulatory structure. The 2021 session brought full legalization. On April 7, 2021, Governor Ralph Northam signed House Bill 2312 and Senate Bill 1406, legalizing possession of up to one ounce of marijuana and cultivation of up to four plants per household for adults 21 and older, effective July 1, 2021. The legislation made Virginia the first Southern state to legalize adult-use cannabis and the 16th state nationally. Critically, the 2021 legislation separated possession legalization from retail sales. The bills established the Virginia Cannabis Control Authority to develop regulations for a commercial market but delayed retail sales until January 1, 2024, pending regulatory development. The legislation directed the Authority to prioritize social equity applicants—individuals from communities disproportionately impacted by marijuana prohibition—for 30 percent of retail licenses.

Retail Market Stalemate (2022-Present)

The Cannabis Control Authority began accepting applications for conditional licenses in 2022, ultimately issuing approximately 450 conditional retail licenses, 200 conditional cultivation licenses, and 100 conditional processing licenses. However, the General Assembly has repeatedly failed to pass enabling legislation to convert conditional licenses into operational permits. In 2022, newly elected Governor Glenn Youngkin, a Republican who opposed legalization during his campaign, signaled he would not support retail sales legislation. The Republican-controlled House of Delegates blocked multiple bills to establish the retail market in 2022, 2023, 2024, and 2025. Democrats, who controlled the Senate until 2024, passed retail implementation bills in 2022 and 2023, but the House refused to advance them. The 2024 elections gave Republicans control of both chambers, further dimming prospects for retail legalization. As of June 2026, Virginia remains in a unique position: adults may legally possess and cultivate marijuana but have no legal source to purchase it, while conditional license holders have invested an estimated $50 million in application fees, legal costs, and site preparation for businesses that cannot open.

Hemp Industry Boom and Regulatory Backlash (2018-Present)

The 2018 federal Farm Bill legalized hemp cultivation and removed hemp-derived cannabinoids from Schedule I of the Controlled Substances Act, defining hemp as cannabis containing no more than 0.3 percent delta-9 THC by dry weight. Virginia quickly established a hemp cultivation program under the Virginia Department of Agriculture and Consumer Services, issuing over 1,000 grower registrations by 2020. Entrepreneurs discovered loopholes in the 0.3 percent definition, synthesizing intoxicating cannabinoids like delta-8 THC, delta-10 THC, THC-O, and THCP from CBD isolate derived from legal hemp. These products—sold as gummies, vapes, and tinctures—produce psychoactive effects similar to delta-9 THC but remained legal under federal and Virginia law because they derived from hemp and contained less than 0.3 percent delta-9 THC. Virginia's hemp-derived intoxicant market exploded. By 2023, over 2,000 retail locations sold delta-8 products, including gas stations, smoke shops, and dedicated hemp retailers. The Virginia Hemp Coalition estimated the market at $150 million annually. However, the products faced no testing requirements, no age restrictions beyond voluntary retailer policies, and no potency limits. The 2024 General Assembly passed House Bill 698, directing the Board of Pharmacy to regulate hemp-derived intoxicants as controlled substances. The bill required retailers to obtain permits, restricted sales to adults 21 and older, and mandated third-party laboratory testing. However, the legislation contained no enforcement mechanism and no penalties for non-compliance, rendering it largely symbolic. The Board of Pharmacy issued proposed regulations in November 2024 but has not finalized them as of June 2026.

Key Players

Virginia Cannabis Control Authority

The Cannabis Control Authority, established by the 2021 legalization legislation, operates as an independent agency responsible for regulating medical and adult-use cannabis. The Authority is governed by a five-member board appointed by the Governor, with members representing law enforcement, public health, agriculture, and social equity constituencies. Executive Director Aaron Bowles, appointed in 2022, oversees a staff of approximately 40 employees and an annual budget of $8 million funded by medical dispensary fees. The Authority has issued conditional licenses but lacks statutory authority to convert them to operational permits without further General Assembly action. The agency has focused on medical program expansion, increasing registered patients from 8,000 in 2020 to approximately 50,000 in 2026, but remains hamstrung on adult-use implementation.

Virginia Department of Agriculture and Consumer Services

VDACS administers the hemp cultivation program under the 2018 Farm Bill framework. The agency registers hemp growers, samples crops for THC compliance, and enforces the 0.3 percent delta-9 THC limit. Commissioner of Agriculture Joseph Guthrie has publicly expressed concern about federal rescheduling impacts on Virginia's hemp farmers, warning in May 2026 testimony to the House Agriculture Committee that DEA reclassification could subject hemp to pharmaceutical regulations that would devastate the industry. VDACS registered 487 hemp growers cultivating 2,800 acres in 2025, down from 1,100 growers and 8,100 acres in 2019. The decline reflects market consolidation, banking challenges, and regulatory uncertainty.

Medical Pharmaceutical Processors

Virginia's four licensed medical processors operate as vertically integrated monopolies, each serving a geographic region. Dharma Pharmaceuticals, based in Bristol, serves Southwest Virginia and operates two dispensaries. Columbia Care, a multi-state operator headquartered in New York, operates three Virginia dispensaries in Portsmouth, Manassas, and Chesapeake. Green Leaf Medical operates three dispensaries in Richmond, Fredericksburg, and Roanoke. gLeaf Medical Virginia operates three dispensaries in Salem, Harrisonburg, and Richmond. These processors collectively generated approximately $120 million in sales in 2025, according to Cannabis Control Authority data. They pay a 6 percent excise tax on gross receipts, producing $7.2 million in state revenue. The processors have lobbied against adult-use retail legalization, arguing that their existing infrastructure should receive priority in any expanded market.

Virginia Hemp Coalition

The Virginia Hemp Coalition represents approximately 200 hemp farmers, processors, and retailers. Executive Director Jason Amatucci has advocated for clear federal and state regulations that preserve hemp's legal status while addressing intoxicating cannabinoid concerns. The Coalition supported the 2024 regulatory framework but has criticized the lack of enforcement and the threat of federal preemption.

Drug Enforcement Administration

The DEA's proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, announced in May 2024, threatens to upend Virginia's hemp industry. If finalized, Schedule III classification would subject all cannabis—including hemp—to pharmaceutical manufacturing standards under 21 U.S.C. § 812 and 21 C.F.R. § 1308. Hemp farmers and processors argue they cannot comply with Good Manufacturing Practice requirements designed for pharmaceutical facilities, effectively criminalizing the industry Congress legalized in 2018. The DEA accepted public comments on the proposed rule through July 2024, receiving over 45,000 submissions. The agency has not announced a timeline for final rulemaking as of June 2026, leaving the industry in limbo.

General Assembly Leadership

House Speaker Todd Gilbert, a Republican from Shenandoah County, has blocked adult-use retail legislation since taking the speakership in 2022. Gilbert has stated that retail sales are "not a priority" and that the 2021 legalization was "premature." Senate Majority Leader Scott Surovell, a Democrat from Fairfax County, championed retail implementation bills in 2022 and 2023 but lost his majority in 2024. Governor Glenn Youngkin has not publicly supported retail sales and has signaled he would veto legislation lacking strict regulatory controls.

Legal and Regulatory Framework

Virginia's cannabis law comprises a patchwork of statutes governing possession, cultivation, medical access, hemp, and an unimplemented retail structure.

Adult-Use Possession and Cultivation

Virginia Code § 4.1-600 et seq., enacted by House Bill 2312 (2021), legalizes possession of up to one ounce of marijuana for adults 21 and older. Possession of more than one ounce but less than one pound is a civil violation punishable by a $25 fine. Possession of one pound or more remains a felony under § 18.2-248.1, punishable by up to 10 years imprisonment. Section 4.1-600 permits cultivation of up to four marijuana plants per household, with a maximum of two mature plants. Plants must be cultivated in a locked space inaccessible to minors. Cultivation of more than four plants but fewer than 10 is a civil violation; 10 or more plants constitutes felony manufacturing under § 18.2-248.1. Public consumption remains prohibited under § 4.1-600(D), punishable by a $25 civil penalty. Driving under the influence of marijuana is a Class 1 misdemeanor under § 18.2-266, with a per se limit of 3 nanograms of THC per milliliter of blood.

Medical Cannabis Program

Virginia Code § 54.1-3408.3 authorizes the Board of Pharmacy to register pharmaceutical processors to cultivate, process, and dispense cannabis for medical use. Registered patients must obtain a written certification from a licensed practitioner for any diagnosed condition or disease. There are no specific qualifying conditions; practitioner discretion governs eligibility. Patients register with the Board of Pharmacy and receive a registration card valid for one year. As of June 2026, registration costs $50 annually, with no fee for patients receiving Medicaid or Supplemental Security Income. Patients may possess up to a 90-day supply as determined by their practitioner. Pharmaceutical processors pay a 6 percent excise tax on gross receipts under § 4.1-1604. They must comply with pharmaceutical-grade manufacturing standards and submit to unannounced inspections by the Board of Pharmacy.

Hemp Regulation

Virginia Code § 3.2-4112 et seq. implements the 2018 federal Farm Bill, authorizing hemp cultivation for persons registered with VDACS. Hemp is defined as cannabis containing no more than 0.3 percent delta-9 THC on a dry weight basis, consistent with 7 U.S.C. § 1639o. House Bill 698 (2024) added § 54.1-3446, directing the Board of Pharmacy to regulate hemp-derived intoxicants. The statute requires retailers to obtain permits, restricts sales to adults 21 and older, and mandates testing for potency, pesticides, and heavy metals. However, the statute contains no penalties for violations and no appropriation for enforcement, rendering it largely unenforceable.

Federal Controlled Substances Act

Marijuana remains a Schedule I controlled substance under 21 U.S.C. § 812, defined as having no accepted medical use and high potential for abuse. The DEA's proposed rescheduling to Schedule III, published in the Federal Register on May 16, 2024 (89 Fed. Reg. 44,670), would reclassify marijuana alongside anabolic steroids and ketamine. Schedule III substances require prescriptions, and manufacturers must register with the DEA and comply with Good Manufacturing Practice standards under 21 C.F.R. § 1308. The proposed rule does not address hemp's status under the 2018 Farm Bill. Industry advocates argue that rescheduling marijuana to Schedule III does not affect hemp, which Congress explicitly removed from the Controlled Substances Act. However, the DEA has not clarified whether hemp-derived intoxicants would remain legal under a Schedule III framework, creating existential uncertainty for Virginia's hemp industry.

State-by-State Context

Virginia's regulatory paralysis contrasts sharply with neighboring states that have implemented functional adult-use markets or maintained clear prohibition.

Maryland

Maryland legalized adult-use cannabis by referendum in November 2022, with retail sales launching July 1, 2023. The state issued over 100 retail licenses in the first year, generating $157 million in excise tax revenue in fiscal year 2025. Maryland's proximity to Northern Virginia has created a cross-border market, with Virginia residents driving to dispensaries in College Park, Rockville, and Silver Spring. Maryland law prohibits sales to out-of-state residents, but enforcement is minimal.

Washington, D.C.

The District of Columbia legalized possession and home cultivation by Initiative 71 in 2015, but Congress has blocked retail sales through annual appropriations riders. D.C. operates a "gifting" market where businesses sell unrelated products (t-shirts, stickers) and "gift" cannabis, exploiting a loophole in Initiative 71. This gray market generated an estimated $600 million in sales in 2025. Virginia residents in Arlington, Alexandria, and Fairfax County frequently cross into D.C. to access the gifting market.

North Carolina

North Carolina has not legalized marijuana for any purpose. Possession of any amount is a criminal misdemeanor, and the state operates no medical program. However, North Carolina has not restricted hemp-derived intoxicants, creating a thriving delta-8 market. Virginia hemp retailers near the North Carolina border report significant cross-border sales to North Carolina residents.

West Virginia

West Virginia legalized medical cannabis in 2017, with dispensaries opening in 2021. The state has not decriminalized or legalized adult-use possession. West Virginia's medical program is more restrictive than Virginia's, with a closed list of qualifying conditions and higher costs, driving some West Virginia patients to Virginia's medical dispensaries.

Tennessee

Tennessee prohibits marijuana for all purposes and criminalizes possession of any amount. However, Tennessee has not restricted hemp-derived intoxicants, and delta-8 products are widely available. Virginia hemp retailers in Southwest Virginia report sales to Tennessee residents who cross the border to purchase products unavailable in their home state.

Market and Business Implications

Virginia's regulatory stalemate has created a fragmented market where medical operators thrive, hemp retailers face existential threats, and adult-use entrepreneurs hold worthless licenses.

Medical Market Stability

Virginia's four pharmaceutical processors operate a stable oligopoly. With no adult-use competition and limited license issuance, they face minimal market pressure. Average medical cannabis prices in Virginia are $50 to $60 per eighth ounce, approximately 30 percent higher than adult-use prices in Maryland and Washington, D.C. The processors have invested in cultivation expansion, with Green Leaf Medical opening a 100,000-square-foot facility in Powhatan County in 2024 and Columbia Care expanding its Portsmouth operation by 50,000 square feet in 2025. The medical market's growth trajectory is limited by Virginia's small patient population relative to other medical states. Virginia's 50,000 registered patients represent 0.6 percent of the state's population, compared to 3.2 percent in Maryland and 2.8 percent in Pennsylvania. Industry analysts attribute the low participation to stigma, cost, and the availability of unregulated hemp alternatives.

Hemp Industry Crisis

Virginia's hemp industry faces a three-front crisis: federal rescheduling uncertainty, state regulatory ambiguity, and market saturation. Hemp farmers saw wholesale biomass prices collapse from $40 per pound in 2019 to $2 per pound in 2025 as national oversupply and synthetic cannabinoid competition eroded demand. Many farmers have abandoned hemp for traditional crops; Virginia's hemp acreage declined 65 percent from 2019 to 2025. Hemp retailers selling delta-8 and other intoxicants operate in a legal gray zone. The 2024 regulatory framework requires permits and testing but contains no enforcement mechanism. Most retailers have not obtained permits or tested products, gambling that the state will not enforce the law. However, the DEA's proposed rescheduling could instantly criminalize their inventory if hemp-derived intoxicants are deemed Schedule III substances. Banking remains a critical challenge. Federal financial institutions treat hemp-derived intoxicants as high-risk due to their psychoactive effects, denying accounts to hemp retailers and processors. Virginia hemp businesses operate on a cash basis, limiting growth and increasing security risks.

Conditional License Holders in Limbo

Virginia's 450 conditional retail license holders have invested an estimated $50 million in application fees, legal costs, real estate deposits, and architectural plans for businesses that cannot open. The Cannabis Control Authority has not provided a timeline for converting conditional licenses to operational permits, and many license holders have exhausted their capital waiting for legislative action. Social equity applicants—individuals from communities disproportionately impacted by prohibition—face particular hardship. The 2021 legislation prioritized social equity applicants for 30 percent of licenses, but without an operational market, these applicants cannot access the economic opportunities the program promised. Many have taken jobs in other states' cannabis industries, and Virginia risks losing a generation of equity entrepreneurs to jurisdictions with functional markets.

Illicit Market Persistence

Virginia's failure to establish legal retail sales has sustained a robust illicit market. The Virginia State Police estimate that 80 percent of cannabis consumed in Virginia is purchased through illicit channels, including unlicensed dealers, out-of-state purchases, and home cultivation exceeding legal limits. The illicit market generates an estimated $1.5 billion in annual sales, producing zero tax revenue and no consumer protections.

What Experts Say

Industry stakeholders, policymakers, and advocates offer divergent perspectives on Virginia's regulatory future. Jason Amatucci, executive director of the Virginia Hemp Coalition, said in June 2026 testimony to the Senate Agriculture Committee that federal rescheduling poses an existential threat to Virginia's hemp farmers. According to Amatucci, if the DEA finalizes Schedule III classification without exempting hemp, farmers will face a choice between destroying crops or violating federal law. He urged the General Assembly to pass legislation clarifying that hemp remains legal regardless of federal marijuana scheduling. Aaron Bowles, executive director of the Cannabis Control Authority, told the House Appropriations Committee in February 2026 that the agency is prepared to launch the adult-use market within 90 days of receiving legislative authorization. According to Bowles, the Authority has drafted regulations, trained inspectors, and established a seed-to-sale tracking system. However, he acknowledged that conditional license holders may not have the capital to open after years of waiting, potentially requiring a new application process. Delegate Paul Krizek, a Democrat from Fairfax County who sponsored retail implementation legislation in 2023 and 2024, said in a May 2026 interview with the Virginia Mercury that Republican opposition to retail sales is "ideological, not practical." According to Krizek, polling shows that 68 percent of Virginians support legal cannabis sales, but Republican leadership prioritizes cultural conservatism over voter preferences and fiscal benefits. Jenn Michelle Pedini, executive director of Virginia NORML, said in June 2026 that Virginia's current system is "the worst of all worlds." According to Pedini, adults can possess marijuana but have no legal source, creating confusion and sustaining illicit markets. She argued that the General Assembly's failure to implement retail sales has undermined the intent of legalization and perpetuated the harms of prohibition. Dr. Melissa Merritt, a Richmond-based physician who certifies medical cannabis patients, told the Richmond Times-Dispatch in April 2026 that Virginia's medical program serves patients effectively but remains inaccessible to many due to cost and stigma. According to Merritt, patients pay $300 to $500 monthly for medical cannabis, compared to $50 to $100 for prescription pharmaceuticals, and insurance does not cover cannabis. She supports adult-use retail sales as a means to increase access and reduce prices through competition.

What's Next

Virginia's cannabis landscape faces three critical decision points in the next 18 months: federal rescheduling finalization, the 2027 General Assembly session, and potential ballot initiatives.

Federal Rescheduling Timeline

The DEA must finalize its marijuana rescheduling rule following the public comment period that closed in July 2024. The agency typically takes 12 to 24 months to review comments and issue a final rule, suggesting a decision between July 2025 and July 2026. However, as of June 2026, the DEA has not announced a timeline. If the agency finalizes Schedule III classification without clarifying hemp's status, Virginia's hemp industry could face immediate legal jeopardy, forcing the General Assembly to respond in an emergency session. Industry observers expect legal challenges to any final rule. Hemp industry groups have indicated they will sue to preserve hemp's exemption from the Controlled Substances Act, arguing that the 2018 Farm Bill explicitly removed hemp from DEA jurisdiction. Such litigation could take years to resolve, prolonging uncertainty.

2027 General Assembly Session

The 2027 General Assembly session, convening in January 2027, represents Virginia's next opportunity to authorize adult-use retail sales. Democrats must retake at least one chamber in the November 2026 elections to advance legalization legislation. Current polling shows competitive races in suburban Richmond, Northern Virginia, and Hampton Roads districts that could flip control. If Democrats gain a majority, they are expected to prioritize retail implementation legislation in the first weeks of the session. However, Governor Youngkin's veto power remains a significant obstacle. A two-thirds supermajority in both chambers is required to override a veto, a threshold Democrats are unlikely to reach even in an optimistic election scenario. Alternatively, the General Assembly could place a constitutional amendment on the 2027 ballot, asking voters to affirm or reject cannabis legalization. Such a referendum would bypass the Governor and establish a clear popular mandate, but it would delay retail sales until at least 2028.

Regulatory Developments

The Board of Pharmacy is expected to finalize hemp-derived intoxicant regulations by September 2026, according to the agency's regulatory agenda. However, without enforcement funding or penalties, the regulations may have minimal impact. The General Assembly could appropriate funds for enforcement in the 2027 session, but Republican leadership has shown little interest in regulating hemp beyond symbolic gestures. The Cannabis Control Authority plans to issue updated medical cannabis regulations in late 2026, potentially expanding the number of dispensary locations and allowing delivery services. These changes would improve medical access but would not address the adult-use market stalemate.

Market Scenarios

Three scenarios are plausible over the next two years: Scenario 1: Retail Implementation (30 percent probability). Democrats retake the General Assembly in November 2026, pass retail sales legislation in early 2027, and override a gubernatorial veto or negotiate compromise language. Retail sales launch in late 2027 or early 2028, with conditional license holders receiving priority. The market generates $200 million in first-year sales and $20 million in tax revenue. Scenario 2: Continued Stalemate (50 percent probability). Republicans maintain control of the General Assembly, and no retail legislation advances. The medical market continues to grow slowly, hemp retailers operate in a gray zone, and the illicit market persists. Federal rescheduling occurs but exempts hemp, preserving the status quo. Virginia remains an outlier with legal possession but no legal sales. Scenario 3: Federal Preemption (20 percent probability). The DEA finalizes Schedule III classification and asserts jurisdiction over hemp-derived intoxicants, effectively criminalizing Virginia's hemp industry. The General Assembly convenes an emergency session to address the crisis, potentially accelerating adult-use retail implementation as a replacement market for displaced hemp businesses.

Further Reading

• Virginia Cannabis Control Authority official website: https://www.cca.virginia.gov
• Virginia Code § 4.1-600 et seq. (adult-use cannabis): https://law.lis.virginia.gov/vacode/title4.1/chapter6/
• Virginia Code § 54.1-3408.3 (medical cannabis): https://law.lis.virginia.gov/vacode/54.1-3408.3/
• Virginia Department of Agriculture and Consumer Services hemp program: https://www.vdacs.virginia.gov/plant-industry-services-hemp.shtml
• DEA proposed marijuana rescheduling rule, 89 Fed. Reg. 44,670 (May 16, 2024): https://www.federalregister.gov/documents/2024/05/16/2024-10521/schedules-of-controlled-substances-rescheduling-of-marijuana
• 2018 Agriculture Improvement Act (Farm Bill), 7 U.S.C. § 1639o: https://www.congress.gov/bill/115th-congress/house-bill/2
• Virginia NORML: https://www.vanorml.org
• Virginia Hemp Coalition: https://www.virginiahempcoalition.org
• Joint Legislative Audit and Review Commission cannabis study (2020): http://jlarc.virginia.gov/cannabis.asp
• Virginia Mercury cannabis coverage: https://www.virginiamercury.com/category/cannabis